Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma
Natasha K Brockwell, Muhammad Alamgeer, Beena Kumar, Gareth Rivalland, Thomas John, Belinda S Parker
TRANSLATIONAL LUNG CANCER RESEARCH | AME PUBL CO | Published : 2020
Background: Malignant pleural mesothelioma (MPM) is well known as an aggressive disease with poor survival. This has sparked trials of alternate immune-based therapies in MPM. While up to a quarter of MPM patients respond to immune checkpoint inhibitors (ICIs), predicting response remains challenging and PD-L1 expression alone has been deemed insufficient. Additionally, patients with sarcomatoid MPM are often excluded from trials utilizing ICIs due to their rapid progression. Here, we analyze the association of T lymphocytes with response to ICI-based immunotherapy to uncover predictive immune markers across subtypes. Methods: Retrospective analysis of immunotherapy treated mesothelioma pati..View full abstract
Related Projects (1)
Fellowship funding to B.S.P (ARC Future Fellowship, Victorian Cancer Agency Mid-career Fellowship).